The Great Isolate Debate

 

 

CBD may have strong benefits – but does it need help from other cannabinoids?

Beauty retailing behemoth Sephora unwittingly waded into one of the fiercest debates in cannabis earlier this year when it announced that it would stock only full- or broad-spectrum CBD products. Some cheered, calling it validation of the alleged “entourage effect” — synergy among the cannabis plant’s dozens of cannabinoids — and a win for whole-plant-products. Others point out that the “entourage effect” remains unsettled science and that isolated CBD has therapeutic benefits and is best for precise dosing – perhaps why the only FDA-approved CBD treatment is an isolate product, Epidiolex. Many mainstream retailers and prominent spa chains insist on isolated CBD, saying some customers want a guarantee that hemp products contain not even a trace of THC.

The debate has hemp growers and processors wondering where the market is headed. In this webinar, we hear from CBD manufacturers who say isolate products’ days are numbered, versus those who say the market for isolate isn’t going anywhere. After the manufacturers make their cases for the future of CBD extraction, we invite readers to weigh in on where they see the industry headed.

Moderator: Kristen Nichols, Hemp Industry Daily Editor

Guests: Tim Gordon and Hunter Land